Harbor MedTech, Inc. is a fully integrated, commercial-stage regenerative medicine company. We currently have two FDA-cleared and CE marked products and a broad pipeline, all leveraging our patented BriDGE® technology.
The BriDGE® Process transforms standard type-1 collagen into a bio-friendly, stabilized collagen matrix which acts as a trigger to activate the patient’s own healing cascade.
Early Mechanism of Action work performed by Dr. Chandan Sen, at the Regenerative Medicine Center at The Ohio State University, on our first BriDGE® technology product, Architect®, has been shown to accelerate wound healing and limit the formation of biofilm often in a single application.
Our product pipeline uses the BriDGE® platform to create innovative solutions for unmet needs in breast reconstruction, hernia repair, Achilles tendon and rotator cuff repair, wounds, and many other applications in dermatology, general surgery, and plastic surgery.